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ing urgent CABG for failed PTCS.3 Their operative
mortality rate of treated versus placebo groups is disturb-
ing (placebo 8% versus treated 29.4% for bolus plus
infusion). Claims by the EPIC investigators that these
results are acceptable are contradicted by their quoted
references. Eight references had operative mortality rates
ranging from 0% to 6.3%. In the remaining two, the Mid
America Heart group had a total series operative mortal-
ity rate of 6.3% (18/286).4 Of the 113 emergency CABGs,
45% were performed on patients in cardiogenic shock
(mortality rate 15%) or receiving cardiopulmonary resus-
citation (mortality rate 62%). The remainder of patients
undergoing emergency CABG had a mortality rate of 3%
to 4%. The Mid America Heart group quote the mortality
rate for the 1983 National Heart and Lung Institute
percutaneous transluminal coronary angioplasty surgical
registry as 6.9%. In the series of Buffet and coworkers,5 all
were emergency cases; 23% of patients were in cardio-
genic shock or requiring cardiopulmonary resuscitation.
Excluding these cases in extremis, accounting for 14 of 19
deaths, the operative mortality rate for the remainder of
emergency cases was 6.5%.
Thus, the 29.4% operative mortality rate of the EPIC
trial is not reflective of the published mortality rates of 3%
to 6% for the same group of patients undergoing CABG,
particularly because the EPIC patients are not compara-
ble with the in extremis cases reported on by Buffet and
coworkers5 and the Mid America Heart Institute.4 This
30-day, nominal 4% to 6% benefit attributed to abciximab
for PTCS must be questioned if surgical mortality rate is
increased among those needing CABG for failed PTCS.
In addition, blood transfusion costs were $23,500 Aus-
tralian, the cost of abciximab was $1500 Australian/case,
and three patients were exposed to 131 donors. In Aus-
tralian public hospitals, $28,000 Australian would cover
70% of the cost of all three CABGs. Trials analyzing the
effects of this drug must include data on patients who
required urgent CABG if sensible conclusions are to be
reached. Before giving abciximab, the cardiologist must
therefore critically assess the risk of PTCS failure, because
the impact of abciximab on CABG is not benign.
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Brain natriuretic peptide (BNP), a recently discovered
cardiac hormone, is secreted mainly by the cardiac ventri-
cles and has potent diuretic, natriuretic, and vasorelaxant
properties. Circulating BNP levels are increased in pa-
tients with heart failure in proportion to the severity of the
disease and may have important compensatory renal,
cardiovascular, and endocrinologic actions. Cardiac trans-
plantation, a recognized treatment for end-stage heart
failure, normalizes the neuroendocrine balance, but atrial
natriuretic peptide and BNP levels remain elevated in
heart-transplant recipients.1 Contrasting with the numer-
ous studies focused on atrial natriuretic peptide in heart
transplantation2 and despite the greater potential benefi-
cial effects of BNP, few data are available concerning the
BNP level response to cardiac transplantation.3, 4
Method and results. Plasma BNP levels were deter-
mined by radioimmunoassay with kits from Peninsula
Laboratories (Belmont, Calif.) after extraction by Sep Pak
C18 cartridges (Waters Chromatography, Milford, Mass.)
in 25 patients just before and daily during the first week
after either heart transplantation (n 5 15) or coronary
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artery bypass grafting (CABG, n 5 10). Patients under-
going CABG served as a control group to differentiate any
hormonal effects of cardiac surgery per se from specific
effects of transplantation. Cardiovascular hemodynamics,
plasma creatinine level (used as an index of renal func-
tion), endothelin level, and medications were measured
simultaneously. The study was approved by the institu-
tional review board, and each patient gave informed
consent.
Fig. 1 shows that plasma BNP level tended to decrease
partially and transiently after transplantation, in opposi-
tion to the increase observed after CABG. Table I pre-
sents the beneficial hemodynamic effects of heart trans-
plantation. CABG transiently increased the heart rate but
did not modify the systemic blood pressure; right ventric-
ular hemodynamics were not determined. Serum creati-
nine level, not modified after CABG, tended to increase
after transplantation. As previously reported, endothelin
level increased progressively after operation.2 Positive
correlations were observed between systolic, diastolic, and
mean pulmonary artery pressures and BNP level (r 5 0.57,
p 5 0.01; r 5 0.45, p 5 0.04; and r 5 0.47, p 5 0.04,
respectively) and capillary wedge pressure and BNP level
(r 5 0.49, p 5 0.03) when considering the acute effect of
transplantation (day 0 and day 1). Among the usual
first-week chronotropic and inotropic drug support, only
isoproterenol (INN: isoprenaline) and dopamine corre-
lated with plasma BNP level in heart transplantation (r 5
0.57, p , 0.0001, and r 5 0.23, p , 0.02, respectively). No
significant correlation was observed between BNP level
and azathioprine, prednisolone, or cyclosporine (INN:
ciclosporin), but BNP level was positively correlated with
serum creatinine and endothelin levels (r 5 0.60, p ,
0.0001, and r 5 0.55, p 5 0.002, respectively).
Discussion. This study confirms that plasma BNP levels
are elevated in heart transplantation. It supports, for the
first time, the contention that the hemodynamic improve-
ment after cardiac transplantation may partially decrease
circulating BNP levels early after the operation. Indeed,
we observed positive correlations between BNP level and
decreased pulmonary capillary wedge and pulmonary
artery pressures in heart transplantation. Accordingly, the
right ventricle has been shown to participate in BNP
secretion after heart transplantation,3 and increased
plasma BNP levels were recently reported to be associated
with increased right ventricular afterload in heart trans-
plantation.4
Several factors acting on BNP clearance and secretion
rates may explain why BNP level decreases only partially
and transiently after transplantation. BNP is cleared by
the kidney, and moderate renal failure, as inferred from
increased creatinine level, may partially explain the sec-
ondary increase of the cardiac hormone. Endothelin may
participate in BNP level elevation in heart transplanta-
tion, both through its deleterious renal effects and through
direct stimulation of BNP secretion. BNP levels after
cardiac transplantation may also reflect predominantly
right and left ventricular diastolic function.4 Indeed, BNP
level is elevated in patients with isolated diastolic dysfunc-
tion,5 and it is well known that, in addition to normalizing
systolic function, heart transplantation results in diastolic
dysfunction. This may explain the need for drug support
and the positive correlation observed between BNP level
and isoproterenol. Although positive correlation between
BNP level and trough cyclosporine levels has not consis-
tently been reported,3, 4 it is tempting to speculate that
cyclosporine may participate in BNP level increase in our
heart transplantation group, because BNP level increased
when cyclosporine therapy was began (day 4). In this view,
the lack of correlation between BNP level and cyclospor-
ine in our heart transplantation group may rely on the fact
that peak levels or local tissue concentrations of cyclo-
sporine, rather than 12-hour trough level, may be better
for cyclosporine effect assessment.
In summary, an early determination of BNP level after
transplantation allowed us to observe transient changes
that might otherwise have been missed. The results sug-
gest that hemodynamic improvement after heart trans-
plantation reduces plasma BNP levels and that impaired
renal function, increased endothelin level, and diastolic
dysfunction increase the cardiac hormone early after heart
transplantation. Systemic hypertension, occurring later
Fig. 1. Plasma BNP concentrations (mean 6 standard
error of the mean) before (D0) and during the days (D1 to
D8) after heart transplantation (:, n 5 9 before and n 5
15 after) and CABG (j, n 5 10). For differences between
patients undergoing heart transplantation and those un-
dergoing CABG, asterisk indicates p , 0.0001, dagger
indicates p 5 0.03, and double dagger indicates p , 0.0001.
The dotted lines show the 95% range of variation of
normal values obtained in healthy subjects.
Table I. Time course of hemodynamic parameters
before and after heart transplantation
Before POD I POD 4 POD 8
p
Value
sPAP (mm Hg) 48 6 5 34 6 2* 31 6 3* — 0.002
PCWP (mm Hg) 24 6 3 10 6 1* 13 6 1* — ,0.0001
sSBP (mm Hg) 120 6 3 124 6 5 133 6 5 131 6 4 0.06
HR (beats/min) 81 6 4 128 6 3* 109 6 2* 91 6 3 ,0.0001
Data are mean 6 standard error of the mean. Differences between groups
were obtained by one-way ANOVA with repeated measures on time.
When probability was lower than 0.05, pairwise comparisons with before
value were assessed by Tukey’s test. POD, Postoperative day; sPAP, systolic
pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure;
sSBP, systolic systemic blood pressure; HR, heart rate.
*p , 0.01.
The Journal of Thoracic and
Cardiovascular Surgery
February 1998
4 7 4 Brief communications
after transplantation, may then increase diastolic dysfunc-
tion, thus enhancing BNP secretion in heart transplanta-
tion.
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CARDIOPULMONARY BYPASS–INDUCED INCREASE OF SERUM INTERLEUKIN-10 LEVELS IN
CHILDREN
Attila Ta´rnok, PhD, Jo¨rg Hambsch, MD, and Peter Schneider, MD, Leipzig, Germany
During pediatric cardiac operations with cardiopulmo-
nary bypass (CPB), the serum levels of various inflamma-
tory cytokines change dramatically.1 Recent studies in
children demonstrate that interleukin-10 (IL-10), a cyto-
kine that acts in an immunosuppressive manner, is liber-
ated during2 or after3 pediatric cardiac operations. The
information provided by these authors, however, are
conflicting with respect to the amplitude and the kinetics
of secreted IL-10.2, 3 Seghaye and colleagues2 reported
two peaks of IL-10 release, one during and a second after
CPB, with maximums at the end of CPB and 1 day after
the operation, respectively. Data from Sugita and associ-
ates3 indicate earlier IL-10 release, with maximums during
reperfusion and a few hours after the operation. Their
data are similar to data reported for adults4 with respect
to the kinetics of IL-10 release. In contrast, Sugita and
associates3 reported initial and peak IL-10 values that
were more than 10 times as high as in adults4 and in
infants until 10 months after birth.2 We analyzed the
kinetics of IL-10, interleukin-6 (IL-6) and tumor necrosis
factor–a (TNF-a) release in children undergoing cardiac
operations to clarify the release pattern of IL-10 in
children.
Patients and methods. After informed consent was
obtained, 24 children with atrial septal defects (atrial
septal defect I, n 5 1; atrial septal defect II, n 5 13) or
ventricular septal defects (n 5 10) undergoing cardiac
operations were analyzed. The surgical procedures were
ventricular septal defect closure and atrial septal defect
repair, respectively. General anesthesia and myoplegia
were performed with midazolam, fentanyl, and pancuro-
nium. CPB was performed with a roller pump (Sto¨ckert
Instrumente GmbH, Munich, Germany) and hollow-fiber
oxygenator (DIDECO, Mirandola, Italy). The priming
solution consisted of a crystalloid solution, mannitol (3
ml/kg body weight), and Iono-lactat (Fresenius, Bad
Homburg, Germany). In a few cases, priming was com-
pleted with compatible erythrocyte concentrate. During
CPB, the hematocrit level was kept at 22% to 30% and the
flow rate was maintained at 2.7 to 3.5 L/m2/min. Hypo-
thermia was induced by cooling priming solution and
circulating blood with the heat exchanger. During the
cooling period, all patients received sodium nitroprusside
(0.3 to 2.0 mg/kg/min) for vasodilatation. Bretschneider’s
cardioplegic solution was used for myocardial perfusion.
Our perioperative antibiotic regimen consisted of cefazo-
lin (50 mg/kg body weight) in three separate doses. During
rewarming, heated and humidified inspired gases were
used and sodium nitroprusside was administered intrave-
nously. At the end of CPB, all but one patient underwent
hemofiltration, normal flow was reestablished, and the
patients were rewarmed. The lungs were reventilated and
heparin was neutralized with protamine sulfate. In all but
two cases, a catecholamine (dobutamine or dopamine at 2
to 6 mg/kg/min) was infused before the patients were
weaned from bypass. No corticosteroids were applied
before, during, or after the operation.
Blood samples were collected 1 day before the opera-
tion (–1d); after the onset of anesthesia (anesthesia); 10
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